PDL therapy fails endpoints in Phase III

PDL BioPharma says its late-stage trial of an experimental therapy for advanced liver disease failed to meet its primary endpoints. The study evaluated the efficacy of terlipressin on kidney function and survival in patients with Type 1 hepatorenal syndrome. While researchers found positive trends in the data, the results failed to measure up to the statistical significance that was sought. PDL says now that it will discuss the future of the drug with its collaborator, Orphan Therapeutics, before deciding how to proceed. PDL's second-quarter net loss, meanwhile, widened from the year before.

- here's the report on PDL from MarketWatch

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.